Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review

Chavan, 2014, International variations in bladder cancer incidence and mortality, Eur Urol, 66, 59, 10.1016/j.eururo.2013.10.001 Babjuk, 2013, EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013, Eur Urol, 64, 639, 10.1016/j.eururo.2013.06.003 Lerner, 2012, Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder, Urol Oncol, 30, 285, 10.1016/j.urolonc.2010.09.009 Kausch, 2010, Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies, Eur Urol, 57, 595, 10.1016/j.eururo.2009.11.041 Grossman, 2012, Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy, J Urol, 188, 58, 10.1016/j.juro.2012.03.007 Burger, 2013, Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data, Eur Urol, 64, 846, 10.1016/j.eururo.2013.03.059 Geavlete, 2012, Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors–results of a prospective, randomized comparison to the standard approach, Urology, 79, 846, 10.1016/j.urology.2011.08.081 Tatsugami, 2010, Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer, J Endourol, 24, 1807, 10.1089/end.2010.0055 Li, 2013, Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis, Int J Urol, 20, 602, 10.1111/j.1442-2042.2012.03211.x Shen, 2012, Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis, BJU Int, 110, E209, 10.1111/j.1464-410X.2011.10892.x Witjes, 2006, Management of BCG failures in superficial bladder cancer: a review, Eur Urol, 49, 790, 10.1016/j.eururo.2006.01.017 Schrier, 2004, Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy, Eur Urol, 45, 292, 10.1016/j.eururo.2003.10.006 van den Bosch, 2011, Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review, Eur Urol, 60, 493, 10.1016/j.eururo.2011.05.045 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine – levels of evidence (March 2009). Centre for Evidence-based Medicine Web site. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/1998/. Orozco, 1993, The pagetoid variant of urothelial carcinoma in situ, Hum Pathol, 24, 1199, 10.1016/0046-8177(93)90216-4 Nese, 2009, Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis, J Natl Compr Canc Netw, 7, 48, 10.6004/jnccn.2009.0004 Lopez-Beltran, 2011, Flat urothelial carcinoma in situ of the bladder with glandular differentiation, Hum Pathol, 42, 1653, 10.1016/j.humpath.2010.12.024 Lamm, 1998, Updated concepts and treatment of carcinoma in situ, Urol Oncol, 4, 130, 10.1016/S1078-1439(99)00020-4 Sauter, 2004 Chade, 2010, Clinical outcome of primary versus secondary bladder carcinoma in situ, J Urol, 184, 464, 10.1016/j.juro.2010.03.134 Kirkali, 2005, Bladder cancer: epidemiology, staging and grading, and diagnosis, Urology, 66, 4, 10.1016/j.urology.2005.07.062 Murphy, 2002, Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care, J Urol, 168, 968, 10.1016/S0022-5347(05)64553-3 Witjes, 2006, Review pathology in a diagnostic bladder cancer trial: effect of patient risk category, Urology, 67, 751, 10.1016/j.urology.2005.10.028 Sharkey, 1997, The significance of central pathology review in clinical studies of transitional cell carcinoma in situ, J Urol, 157, 68, 10.1016/S0022-5347(01)65282-0 Lee, 2010, The role of pathology review of transurethral bladder tumor resection specimens in the modern era, J Urol, 183, 921, 10.1016/j.juro.2009.11.049 van der Meijden, 1999, Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee, Eur Urol, 35, 267, 10.1159/000019859 May, 2003, Significance of random bladder biopsies in superficial bladder cancer, Eur Urol, 44, 47, 10.1016/S0302-2838(03)00157-X van der Meijden, 2005, EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ, Eur Urol., 48, 363, 10.1016/j.eururo.2005.05.011 Utz, 1970, The plight of the patient with carcinoma in situ of the bladder, J Urol, 103, 160, 10.1016/S0022-5347(17)61913-X Wolf, 1994, Natural history of carcinoma in situ of the urinary bladder, Scand J Urol Nephrol Suppl, 157, 147 Herr, 1983, Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder, Cancer, 51, 1323, 10.1002/1097-0142(19830401)51:7<1323::AID-CNCR2820510724>3.0.CO;2-2 Cookson, 1997, The treated natural history of high risk superficial bladder cancer: 15-year outcome, J Urol, 158, 62, 10.1097/00005392-199707000-00017 Jacobsen, 1985, Flat intra-epithelial carcinoma in situ of the urinary bladder, Scand J Urol Nephrol, 19, 253, 10.3109/00365598509180265 Fukui, 1987, Carcinoma in situ of the urinary bladder. Effect of associated neoplastic lesions on clinical course and treatment, Cancer, 59, 164, 10.1002/1097-0142(19870101)59:1<164::AID-CNCR2820590132>3.0.CO;2-Z Melamed, 1964, Natural history and clinical behavior of in situ carcinoma of the human urinary bladder, Cancer, 17, 1533, 10.1002/1097-0142(196412)17:12<1533::AID-CNCR2820171205>3.0.CO;2-7 Farrow, 1977, Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder, Cancer Res, 37, 2794 Althausen, 1976, Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ, J Urol, 116, 575, 10.1016/S0022-5347(17)58916-8 Prout, 1987, The outcome of conservative treatment of carcinoma in situ of the bladder, J Urol, 138, 766, 10.1016/S0022-5347(17)43366-0 Riddle, 1975, Flat carcinoma in situ of bladder, Br J Urol, 47, 829, 10.1111/j.1464-410X.1975.tb04064.x Solsona, 1990, Biological behavior of untreated bladder carcinoma in situ [in Spanish], Arch Esp Urol, 43, 643 Kurth, 1995, Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra, Int J Urol, 2, 8, 10.1111/j.1442-2042.1995.tb00475.x Bolenz, 2013, Urinary cytology for the detection of urothelial carcinoma of the bladder–a flawed adjunct to cystoscopy?, Urol Oncol, 31, 366, 10.1016/j.urolonc.2011.01.017 Kamat, 2013, ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers, Eur Urol, 63, 4, 10.1016/j.eururo.2012.09.057 Rink, 2013, Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non–muscle-invasive bladder cancer: a critical review of the current literature, Eur Urol, 64, 624, 10.1016/j.eururo.2013.07.007 Bergman, 2008, Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings, BJU Int, 101, 26 Fritsche, 2010, Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder, Am J Clin Pathol, 134, 597, 10.1309/AJCPKKWBDSAOZ4RW Sarosdy, 2002, Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer, J Urol, 168, 1950, 10.1016/S0022-5347(05)64270-X Kamat, 2014, Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer, Eur Urol, 65, 267, 10.1016/j.eururo.2013.10.016 Lamm, 2000, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5 Herr, 2005, Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy, J Urol, 174, 2134, 10.1097/01.ju.0000181799.81119.fc Malmström, 2009, An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer, Eur Urol, 56, 247, 10.1016/j.eururo.2009.04.038 Chade, 2010, Clinical outcomes of primary bladder carcinoma in situ in a contemporary series, J Urol, 184, 74, 10.1016/j.juro.2010.03.032 Jakse, 2001, Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861, Eur Urol, 40, 144, 10.1159/000049765 Griffiths, 2002, Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance, J Urol, 167, 2408, 10.1016/S0022-5347(05)64994-4 Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5 de Reijke, 2005, Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer–Genito-Urinary Group phase III trial (30906), J Urol, 173, 405, 10.1097/01.ju.0000150425.09317.67 Oddens, 2013, Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance, Eur Urol, 63, 462, 10.1016/j.eururo.2012.10.039 van der Heijden, 2004, Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder, Eur Urol, 46, 65, 10.1016/j.eururo.2004.01.019 Witjes, 2009, Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party, World J Urol, 27, 319, 10.1007/s00345-009-0384-2 Di Stasi, 2003, Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study, J Urol, 170, 777, 10.1097/01.ju.0000080568.91703.18 Di Stasi, 2006, Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial, Lancet Oncol, 7, 43, 10.1016/S1470-2045(05)70472-1 Oosterlinck, 2011, Eur Urol, 59, 438, 10.1016/j.eururo.2010.11.038 Kaasinen, 2003, Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study, Eur Urol, 43, 637, 10.1016/S0302-2838(03)00140-4 Jarvinen, 2012, Scand J Urol Nephrol, 46, 411, 10.3109/00365599.2012.694906 Yates, 2012, Treatment options available for bacillus Calmette-Guérin failure in non–muscle-invasive bladder cancer, Eur Urol, 62, 1088, 10.1016/j.eururo.2012.08.055 Merz, 1995, Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder, Br J Urol, 75, 180, 10.1111/j.1464-410X.1995.tb07307.x Giannarini, 2014, Bacillus Calmette-Guérin failure in patients with non–muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra, Eur Urol, 65, 825, 10.1016/j.eururo.2013.09.049 Gallagher, 2008, Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy, Urology, 71, 297, 10.1016/j.urology.2007.09.050 Joudi, 2004, Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures, Curr Opin Urol, 14, 271, 10.1097/00042307-200409000-00005 Joudi, 2006, Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer, Urol Oncol, 24, 344, 10.1016/j.urolonc.2005.11.026 Rosevear, 2011, Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ, J Urol, 186, 817, 10.1016/j.juro.2011.04.073 Bui, 1997, Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response, Urology, 49, 687, 10.1016/S0090-4295(97)00067-8 Bretton, 1990, The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin, J Urol, 143, 710, 10.1016/S0022-5347(17)40067-X Lockyer, 2002, Beware the BCG failures: a review of one institution's results, Eur Urol, 42, 542, 10.1016/S0302-2838(02)00491-8 Steinberg, 2000, Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group, J Urol, 163, 761, 10.1016/S0022-5347(05)67799-3 Dinney, 2013, Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin, Urol Oncol, 31, 1635, 10.1016/j.urolonc.2012.04.010 Di Lorenzo, 2010, Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial, Cancer, 116, 1893, 10.1002/cncr.24914 Dalbagni, 2006, Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder, J Clin Oncol, 24, 2729, 10.1200/JCO.2005.05.2720 Gontero, 2013, Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?, Urol Oncol, 31, 671, 10.1016/j.urolonc.2011.03.011 Skinner, 2013, SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin, J Urol, 190, 1200, 10.1016/j.juro.2013.04.031 Barlow, 2013, Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy, J Urol, 189, 834, 10.1016/j.juro.2012.10.068 Morales, 2009, Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed, J Urol, 181, 1040, 10.1016/j.juro.2008.11.019 Watanabe, 2003, Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder, Cancer Immunol Immunother, 52, 481, 10.1007/s00262-003-0384-9 Saint, 2002, Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer, J Urol, 167, 364, 10.1016/S0022-5347(05)65469-9 Videira, 2009, Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines, Urology, 74, 944, 10.1016/j.urology.2009.02.053 Simons, 2008, Role of neutrophils in BCG immunotherapy for bladder cancer, Urol Oncol, 26, 341, 10.1016/j.urolonc.2007.11.031 Zlotta, 1999, Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guérin intravesical therapy, J Urol, 161, 792, 10.1016/S0022-5347(01)61770-1 Nunez-Nateras, 2014, Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder, Urol Oncol, 32, 10.1016/j.urolonc.2013.06.008 Thomas, 2013, Comparative outcomes of primary, recurrent and progressive high-risk non-muscle invasive bladder cancer, Eur Urol, 63, 145, 10.1016/j.eururo.2012.08.064 De Jager, 1991, Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials, Urology, 38, 507, 10.1016/0090-4295(91)80166-5 Hassan, 2004, Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy, J Urol, 172, 882, 10.1097/01.ju.0000136294.15938.3d Cheng, 1999, Survival of patients with carcinoma in situ of the urinary bladder, Cancer, 85, 2469, 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U Herr, 2001, Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?, J Urol, 166, 1296, 10.1016/S0022-5347(05)65756-4 Saint, 2003, Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist? Analysis of a quarter century of literature, Eur Urol, 43, 351, 10.1016/S0302-2838(03)00048-4 Tilki, 2010, Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients, J Urol, 183, 1757, 10.1016/j.juro.2010.01.025 Shariat, 2006, Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy, Urology, 68, 538, 10.1016/j.urology.2006.03.033 Huang, 2009, Outcomes of patients with clinical CIS-only disease treated with radical cystectomy, World J Urol, 27, 21, 10.1007/s00345-008-0344-2 Zehnder, 2014, Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy, BJU Int, 113, 65, 10.1111/bju.12250 Stein, 2001, Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, 19, 666, 10.1200/JCO.2001.19.3.666 Bruins, 2014, Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study, Urol Oncol, 32, 10.1016/j.urolonc.2012.08.015 Amling, 1994, Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder, J Urol, 151, 31, 10.1016/S0022-5347(17)34865-6 Madersbacher, 2003, Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy, J Clin Oncol, 21, 690, 10.1200/JCO.2003.05.101 Hautmann, 2006, Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era, J Urol, 176, 486, 10.1016/j.juro.2006.03.038 Shariat, 2006, Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium, J Urol, 176, 2414, 10.1016/j.juro.2006.08.004 Ghoneim, 2008, Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later, J Urol, 180, 121, 10.1016/j.juro.2008.03.024 Yafi, 2011, Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience, BJU Int, 108, 539, 10.1111/j.1464-410X.2010.09912.x Isbarn, 2009, Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer, J Urol, 182, 459, 10.1016/j.juro.2009.04.017 Palou, 2007, Urothelial carcinoma of the prostate, Urology, 69, 50, 10.1016/j.urology.2006.05.059 Zincke, 1985, Review of Mayo Clinic experience with carcinoma in situ, Urology, 26, 39 Nixon, 2002, Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder, J Urol, 167, 502, 10.1016/S0022-5347(01)69073-6 Revelo, 2004, Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery, J Urol, 171, 646, 10.1097/01.ju.0000107380.40481.bc Liedberg, 2007, Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection, Scand J Urol Nephrol, 41, 290, 10.1080/00365590601183576 Sakamoto, 1993, An adequate sampling of the prostate to identify prostatic involvement by urothelial carcinoma in bladder cancer patients, J Urol, 149, 318, 10.1016/S0022-5347(17)36068-8 Shen, 2006, Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance, Hum Pathol, 37, 726, 10.1016/j.humpath.2006.01.027 Gudjonsson, 2012, The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS), BJU Int, 110, E41, 10.1111/j.1464-410X.2011.10654.x Wishnow, 1988, Importance of early treatment of transitional cell carcinoma of prostatic ducts, Urology, 32, 11, 10.1016/0090-4295(88)90444-X Mukamel, 1990, Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations, J Urol, 144, 1399, 10.1016/S0022-5347(17)39752-5 Gofrit, 2009, Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?, BJU Int, 103, 905, 10.1111/j.1464-410X.2008.08210.x Herr, 1999, Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome, J Urol, 161, 1854, 10.1016/S0022-5347(05)68826-X